TrialLeukemia2017
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
R Hájek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
65 papers cite itlatest 60 shown
this paperpooled ittrialcites it